Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

Conditions: Bladder Cancer; Glioma; Glioblastoma (GBM); Breast Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer (GC); Pharynx Cancer; Oral Cavity Cancer; Kidney Cancer; Liver Cancer; Lung Cancer (NSCLC); Ovarian Cancer; Pancreatic Cancer; PDAC – Pancreatic Ductal Adenocarcinoma; Prostate Cancer
Interventions: Drug: [64Cu]CM500; Drug: [68Ga]CM500; Device: PET/MR; Device: PET/CT; Procedure: Blood Collection
Sponsors: Lumina Pharmaceuticals Inc; National Cancer Institute (NCI)
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 25, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments